ESMO: Alkermes' major I-O hope sees progress across early cancer tests

ESMO: Alkermes' major I-O hope sees progress across early cancer tests

Source: 
Fierce Biotech
snippet: 

Today, we got the first early look at what ALKS 4230, an engineered interleukin-2 (IL-2) variant immunotherapy, can do at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress.

The data cover a series of targets as well as its use as a monotherapy and in combination with Merck’s blockbuster cancer drug Keytruda.